Lymphoma
Therapeutic area
Hematology
Rare disease
Yes
- Definition
- A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- Yes
- Listing at source
- Listed
- Condition name
- Lymphoma
- Therapeutic area
- Hematology
- lymphoma
- lymphoma
- lymphoma (Hodgkin and non-Hodgkin)
- lymphoma (Hodgkin's and non-Hodgkin's)
- lymphoma, malignant
- lymphomatous
- malignant lymphoma
- MLYM
- Severity
- Severe
- Hematology
- Oncology
- MONDO ID
- MONDO:0005062
- Parent condition
- MONDO:0005157
Related records
Broader conditions (12)
- Cancer or benign tumor
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Hematologic disorder
- Hematopoietic and lymphoid cell neoplasm
- Hematopoietic and lymphoid system neoplasm
- Human disease
- Lymphoid hemopathy
- Lymphoid neoplasm
- Neoplasm
- Neoplastic disease or syndrome
Narrower conditions (257)
- A53 diffuse large B-cell lymphoma
- Acute biphenotypic leukemia
- Acute lymphoblastic leukemia
- Adult acute lymphoblastic leukemia
- Adult lymphoma
- Adult nodular lymphocyte predominant Hodgkin lymphoma
- Adult T-cell leukemia/lymphoma
- Aggressive B-cell non-Hodgkin lymphoma
- Aggressive NK-cell leukemia
- AIDS-related primary central nervous system lymphoma
- ALK-negative anaplastic large cell lymphoma
- ALK-positive anaplastic large cell lymphoma
- ALK-positive large B-cell lymphoma
- Alpha-heavy chain disease
- Anaplastic large cell lymphoma
- Angioimmunoblastic T-cell lymphoma
- Anus lymphoma
- Appendix lymphoma
- B acute lymphoblastic leukemia with DUX4 rearrangement
- B acute lymphoblastic leukemia with PAX5 P80R mutation
Trials (5,008)
- "MIRO" Molecularly Oriented Immuno-radio-therapy
- (CHANT)Real World Study of Duvelisib in the Treatment of Non-Hodgkin's Lymphoma (NHL)
- [68Ga]Ga-PentixaFor-PET Imaging for Staging of Marginal Zone Lymphoma
- 10-Propargyl-10-Deazaaminopterin in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma
- 12-O-Tetradecanoylphorbol-13-acetate in Treating Patients With Hematologic Cancer or Bone Marrow Disorder
- 131I-rituximab for Relapsed or Refractory Marginal Zone B-cell Lymphoma
- 1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation
- 17-AAG in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Hodgkin's Lymphoma
- 17-Dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in Treating Patients With an Advanced Solid Tumor or Lymphoma
- 17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas
- 17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer
- 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma
- 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery
- 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Systemic Mastocytosis
- 18F- Fluorothymidine to Evaluate Treatment Response in Lymphoma
- 18F-FDG PET Radiomics of Diffuse Large B-cell Lymphoma
- 18F-FDG PET Scan and MRI Diffusion.Evaluation of the Early Therapeutic Response of Diffuse Large B-cell Lymphoma
- 18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Diffuse Large B-cell Lymphoma
- 18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Natural Killer/T-cell Lymphoma
- 18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Peripheral T-cell Lymphoma
Approved drugs (18)
- Allopurinol
- Bleomycin sulfate
- Cortisone acetate
- Cyclophosphamide
- Dexamethasone
- Dexamethasone sodium phosphate
- Duvelisib monohydrate
- Hydrocortisone
- Lorlatinib
- Methylprednisolone acetate
- Methylprednisolone sodium succinate
- Plerixafor
- Prednisolone
- Prednisone
- Rasburicase
- Tafasitamab
- Tagraxofusp
- Vinblastine sulfate
Drugs in development (486)
- 1018 ISS Phase 3
- 4G7XH22 Phase 1
- 6-O-benzylguanine Phase 1
- 9-aminocamptothecin Phase 2
- A27.15 Phase 1
- Abemaciclib Phase 1
- Abequolixron Phase 1
- Acalabrutinib Phase 1
- Acalisib Phase 1
- Acetaminophen Phase 2
- Acetylcysteine Phase 1
- ADU-S100 Phase 1
- Aflibercept Phase 1
- AG-270 Phase 1
- Agatolimod sodium Phase 2
- Aldesleukin Phase 3
- Alefacept Phase 1
- Alemtuzumab Phase 3
- Alethine Phase 1
- Alisertib Phase 1
Other linked drugs (11)
- Acimtamig
- Crisantaspase
- Dordaviprone
- Eliglustat
- Glembatumumab vedotin
- Gusacitinib
- INCB-40093
- Leucovorin
- Linperlisib
- Nanatinostat
- Ublituximab